ERBB2 and breast cancer: For instance, the HER2 gene, which is amplified in ~30% of primary BCs [11], has been proven as an actionable target for trastuzumab antibody targeted therapy and lapatinib inhibitor targeted therapy treating patients with HER2-amplified BC [12].